Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction

American Journal of Epidemiology

Volumn 173, Issue 6, 2011, Pages 630-639

  Åsvold, Olav Bjørn ^a   Vatten, Lars J ^a   Romundstad, Pål R ^a   Jenum, Pål A ^a   Karumanchi, S Ananth ^a   Anne, Eskild ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Fetal growth retardation; Placenta; Placental circulation; Placental insufficiency; Transforming growth factor beta; Vascular endothelial growth factors

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; GROWTH RATE; HEALTH RISK; PREGNANCY; RISK FACTOR; SAMPLING; SERUM; CONFIDENCE INTERVAL; GROWTH; HYPERTENSION; MATERNAL HEALTH;

ARTICLE; BLOOD SAMPLING; CIRCULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; INFANT; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL SERUM; NORWAY; PREGNANT WOMAN; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; THIRD TRIMESTER PREGNANCY; ADULT; BLOOD LEVEL; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; NEWBORN; PROSPECTIVE STUDY;

ADULT; ANTIGENS, CD; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; LINEAR MODELS; ODDS RATIO; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTERS; RECEPTORS, CELL SURFACE; RISK FACTORS;

NORWAY;

EID: 79954533425     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq373     Document Type: Article

References (35)

1. McIntire DD, Bloom SL, Casey BM, et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med. 1999;340(16):1234-1238 (Pubitemid 29181643)
2. Baker JL, Olsen LW, Sørensen TI. Weight at birth and allcause mortality in adulthood. Epidemiology. 2008;19(2):197-203 (Pubitemid 351253004)
3. Neerhof MG, Thaete LG. The fetal response to chronic placental insufficiency. Semin Perinatol. 2008;32(3):201-205 (Pubitemid 351637627)
4. Valsamakis G, Kanaka-Gantenbein C, Malamitsi-Puchner A, et al. Causes of intrauterine growth restriction and the postnatal development of the metabolic syndrome. Ann N Y Acad Sci. 2006;1092(1):138-147 (Pubitemid 47092333)
5. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21(5):279-287 (Pubitemid 351652513)
6. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005 (Pubitemid 44343543)
7. Nevo O, Many A, Xu J, et al. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2008;93(1):285-292
8. Poon LC, Zaragoza E, Akolekar R, et al. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn. 2008;28(12):1110-1115
9. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008; 21(1):9-23
10. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316-1324 (Pubitemid 46869870)
11. Smith GC, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol. 2009;21(2):111-116
12. Stepan H, Krämer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2007;92(7):2831-2834 (Pubitemid 47037397)
13. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75(1):1-8 (Pubitemid 350266733)
14. Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol. 2008;172(1):77-85 (Pubitemid 351186370)
15. Crispi F, Domínguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol. 2006;195(1):201-207 (Pubitemid 43927524)
16. Diab AE, El-Behery MM, Ebrahiem MA, et al. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet. 2008;102(2):146-151
17. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196(4):326e1-326e13
18. Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005;90(8):4895-4903 (Pubitemid 41159388)
19. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188(1):177-182 (Pubitemid 36135616)
20. Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89(2):770-775 (Pubitemid 38269892)
21. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88(11):5555-5563 (Pubitemid 37452769)
22. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112(1):51-57 (Pubitemid 46120085)
23. Savvidou MD, Yu CK, Harland LC, et al. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006;195(6):1668-1673 (Pubitemid 44792614)
24. Jenum PA, Stray-Pedersen B, Melby KK, et al. Incidence of Toxoplasma gondii infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol. 1998;36(10):2900-2906 (Pubitemid 28429412)
25. Eskild A, Jenum PA, Bruu AL. Maternal antibodies against cytomegalovirus in pregnancy and the risk of fetal death and low birth weight. Acta Obstet Gynecol Scand. 2005;84(11):1035-1041 (Pubitemid 41564525)
26. Vatten LJ, Eskild A, Nilsen TI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196(3):239.e1-239.e6
27. Skjaerven R, Gjessing HK, Bakketeig LS. Birthweight by gestational age in Norway. Acta Obstet Gynecol Scand. 2000;79(6):440-449 (Pubitemid 30326124)
28. Wathén KA, Tuutti E, Stenman UH, et al. Maternal serumsoluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91(1):180-184 (Pubitemid 43069135)
29. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61-78 (Pubitemid 351287924)
30. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658 (Pubitemid 36278583)
31. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642-649 (Pubitemid 43865232)
32. Clark DE, Smith SK, He Y, et al. Avascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59(6):1540-1548 (Pubitemid 28549874)
33. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160(4):1405-1423 (Pubitemid 34411644)
34. Boutsikou T, Malamitsi-Puchner A, Economou E, et al. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev. 2006;82(4):235-239
35. Bateson P, Barker D, Clutton-Brock T, et al. Developmental plasticity and human health. Nature. 2004;430(6998):419-421 (Pubitemid 38987896)